Encorafenib

• UNSPSC Description:

  Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).

• Target Antigen:

  Raf

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/LGX818.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1

• Molecular Weight:

  540.01

• References & Citations:

  [1]Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1|[2]Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  1269440-17-6